A Randomized Phase II/III Trial of Intraperitoneal Paclitaxel Plus Systemic Treatment vs Systemic Treatment Alone in Gastric Carcinomatosis – STOPGAP II (EA2234) - Summary - MDSpire
Conexiant’s news site is now MDSpire News. Learn more
Advertisement
A Randomized Phase II/III Trial of Intraperitoneal Paclitaxel Plus Systemic Treatment vs Systemic Treatment Alone in Gastric Carcinomatosis – STOPGAP II (EA2234)
Can we lower the chance of gastric cancer from growing or spreading by administering paclitaxel chemotherapy directly into the abdominal cavity in addition to chemotherapy given through a vein in the arm? Will administering paclitaxel chemotherapy directly into the abdominal cavity, in addition to chemotherapy given through a vein in the arm help patients live longer?
To determine whether administering paclitaxel directly into the abdominal cavity in addition to chemotherapy given through a vein can lower the chance of gastric cancer growing or spreading and help patients live longer.
Approach:
Study population: People with gastric adenocarcinoma, gastroesophageal junction adenocarcinoma, and peritoneal carcinomatosis.
Treatment being studied: Paclitaxel administered directly into the abdominal cavity in addition to chemotherapy given through a vein.
Comparison: The study compares this approach with the usual approach for gastric cancer.
Interpretation:
The study is evaluating whether adding paclitaxel administered directly into the abdominal cavity to chemotherapy given through a vein is better or worse than the usual approach for gastric cancer.
Limitations:
The provided context does not report trial results.